Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6 (Q33705446)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6 (English)

1 reference

Europe PubMed Central

28 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Henry Seth Friedman

6

object named as

Henry S Friedman

1 reference

Europe PubMed Central

28 July 2017

Darell D. Bigner

9

object named as

Darell D Bigner

1 reference

Europe PubMed Central

28 July 2017

5

object named as

Allan H Friedman

1 reference

Europe PubMed Central

28 July 2017

David A Reardon

2

object named as

David A Reardon

1 reference

Europe PubMed Central

28 July 2017

Roger E McLendon

7

object named as

Roger E McLendon

1 reference

Europe PubMed Central

28 July 2017

R. Edward Coleman

4

object named as

R Edward Coleman

1 reference

Europe PubMed Central

28 July 2017

Michael R Zalutsky

1

object named as

Michael R Zalutsky

1 reference

Europe PubMed Central

28 July 2017

3

object named as

Gamal Akabani

1 reference

Europe PubMed Central

28 July 2017

author name string

Terence Z Wong

8

1 reference

Europe PubMed Central

28 July 2017

language of work or name

0 references

publication date

12 December 2007

1 reference

Europe PubMed Central

28 July 2017

The Journal of Nuclear Medicine

1 reference

Europe PubMed Central

28 July 2017

49

1 reference

Europe PubMed Central

28 July 2017

1

1 reference

Europe PubMed Central

28 July 2017

30-38

1 reference

Europe PubMed Central

28 July 2017

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

21 June 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

21 June 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

21 June 2018

The promise of targeted {alpha}-particle therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

21 June 2018

Clinical impact and functional aspects of tenascin-C expression during glioma progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

21 June 2018

Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

21 June 2018

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

21 June 2018

Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

21 June 2018

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

21 June 2018

Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

21 June 2018

Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

28 July 2018

Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

28 July 2018

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

30 October 2018

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

30 October 2018

Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

30 October 2018

Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

30 October 2018

Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

30 October 2018

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

30 October 2018

High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

30 October 2018

Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

30 October 2018

Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

30 October 2018

Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

30 October 2018

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

30 October 2018

The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

30 October 2018

Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

30 October 2018

Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

30 October 2018

Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2832604

30 October 2018

Points to consider in the manufacture and testing of monoclonal antibody products for human use (1997). U.S. Food and Drug Administration Center for Biologics Evaluation and Research

1 reference

https://pubmed.ncbi.nlm.nih.gov/18077533

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (α,2n)211At reaction

1 reference

https://pubmed.ncbi.nlm.nih.gov/18077533

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blocking [211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds

1 reference

https://pubmed.ncbi.nlm.nih.gov/18077533

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeted alpha particle immunotherapy for myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18077533

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18077533

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2967/JNUMED.107.046938

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33705446&oldid=1952060106"